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ABSTRACT
Background. Patients who survive an episode of acute kidney injury (AKI) are more likely to have further episodes of AKI. AKI
is associated with increased mortality, with a further increase with recurrent episodes. It is not clear whether this is due to
AKI or as a result of other patient characteristics. The aim of this study was to establish whether recurrence of AKI is an
independent risk factor for mortality or if excess mortality is explained by other factors.
Methods. This observational cohort study included adult people from the Tayside region of Scotland, with an episode of AKI
between 1 January 2009 and 31 December 2009. AKI was defined using the creatinine-based Kidney Disease: Improving
Global Outcomes definition. Associations between recurrent AKI and mortality were examined using a Cox proportional
hazards model.
Results. Survival was worse in the group identified to have recurrent AKI compared with those with a single episode of AKI
[hazard ratio ¼ 1.49, 95% confidence interval (CI) 1.37–1.63; P<0.001]. After adjustment for comorbidities, stage of reference
AKI, sex, age, medicines that predispose to renal impairment or, in the 3 months prior to the reference AKI, deprivation and
baseline estimated glomerular filtration rate (eGFR), recurrent AKI was independently associated with an increase in
mortality (hazard ratio ¼ 1.25, 95% CI 1.14–1.37; P<0.001). Increasing stage of reference AKI, age, deprivation, baseline eGFR,
male sex, previous myocardial infarction, cerebrovascular disease and diuretic use were all associated with an increased
risk of mortality in patients with recurrent AKI.
Conclusions. Recurrent AKI is associated with increased mortality. After adjusting for patient characteristics, the increase
in mortality is independently associated with recurrent AKI and is not solely explained by other risk factors.
Keywords: acute kidney injury, mortality, recurrent acute kidney injury, risk factors, survival
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INTRODUCTION
Acute kidney injury (AKI) is associated with increased risk of
mortality and is predictive of poor prognosis in hospitalized
patients [1, 2]. AKI is also a risk factor for future cardiovascular
disease and progression of chronic kidney disease (CKD) [1].
Longer duration of AKI is associated with worse outcomes com-
pared with those with rapid and sustained reversal to baseline
renal function [3]. Previous work has shown that around 30% of
the patients with AKI who survive initial hospitalization de-
velop a repeated or recurrent episode of AKI [4] and that up to
one-third of older people who were hospitalized with AKI
were re-hospitalized in the following 12 months with a recur-
rent AKI [5].
Episodes of AKI have been shown to have a cumulative ef-
fect in increasing the risk of progression to CKD [5–8], and recur-
rent AKI is associated with increased future mortality in
comparison with individuals who have a single episode of AKI
[4, 5, 7, 9]. The pathogenesis of this is not clearly understood in
humans but may be related to uraemia, the activation of inflam-
mation and fibrosis, and resultant microvascular and endothe-
lial damage that drives progressive renal damage, dysfunction
and future cardiovascular disease [10, 11]. Other studies have
attempted to define the risk factors in the cohort of patients
that go on to develop recurrent AKI [4, 5, 7, 12]. These data are,
however, limited with only a small number of studies focusing
on recurrent AKI and the impact that further episodes of AKI
have after recovery following an initial episode of AKI, with
some inconsistent findings. Studies to date have also focused
only on hospital-based AKI [4, 6–9, 11, 13].
There is a lack of clarity around the association between AKI
and its concomitant adverse outcomes, including mortality. At
present, it is unclear if these adverse outcomes are driven by
AKI, progression to CKD and/or the associated sequelae, or if
AKI is a marker of other comorbidities and patient frailty.
The aims of this study are to assess whether recurrence of
AKI is an independent risk factor for mortality or if excess mor-
tality is explained by other factors.
MATERIALS ANDMETHODS
Study design and setting
Population-level healthcare datasets from the Tayside region of
National Health Service (NHS) Scotland, UK, were used to retro-
spectively identify all residents in Tayside aged 18 years with
biochemical evidence of an episode of AKI between 1 January
and 31 December 2009 (index AKI).
A 6-year period from 1 January 2003 to 31 December 2008
was used to identify patients who had previous biochemical evi-
dence of AKI (recurrent AKI). Patients were followed up until
time of death or 11 January 2019, whichever was sooner. Time
to death or end of follow-up was then calculated from the date
of peak creatinine of the index AKI event.
There was no evaluation of AKI or progression to CKD fol-
lowing the index AKI.
Ethical approval
Data provision and linkage were carried by the University of
Dundee Health Informatics Centre (HIC) [14], with analysis of
anonymized data performed in an ISO27001 and Scottish
Government accredited secure safe haven. HIC Standard
Operating Procedures have been reviewed and approved by the
NHS East of Scotland Research Ethics Service.
AKI definition
AKI was defined using the Kidney Disease: Improving Global
Outcomes (KDIGO) creatinine-based criteria [15], and AKI identi-
fication was conducted using the NHS England AKI algorithm
(Supplementary Data, Figure S1). AKI stage was classified
according to the highest stage of AKI during the AKI episode.
Incident or unique AKI events were defined as an AKI for the
same patient that was >7 days apart. All patients with missing
creatinine measurements in 2008, which meant it was not pos-
sible to calculate a baseline creatinine, and those who received
chronic renal replacement therapy (RRT) during the 2003–15
time period were excluded from the study.
Data sources
Data were linked between the following datasets: Scottish Renal
Registry, Community Health Index (CHI) register, Scottish
Morbidity Record of hospital admissions (SMR01), laboratory
results database, medicines dispensed by community pharma-
cies, General Register Office death database and Scottish Care
Information–Diabetes Collaboration [16].
Patient demographic characteristics including age at refer-
ence AKI, sex and social deprivation based on the Scottish Index
of Multiple Deprivation (SIMD) [17] were obtained from the CHI
register.
The SMR01 data provided information on admission and dis-
charge dates as well as discharge diagnosis (based on
International Classification of Diseases 10th revision codes).
Discharge diagnosis from all admissions prior to the reference
AKI was used to assess each participant’s comorbidities and cal-
culate the Charlson Comorbidity Index score [18, 19] for case-
mix adjustment.
The Modification of Diet in Renal Disease study equation [20]
was used to calculate baseline estimated glomerular filtration
rate (eGFR) using the median creatinine in the previous 8–
365 days or lowest creatinine value in the previous 7 days; if
both were available median creatinine in the previous 8–
365 days was used. Creatinine assays were traceable to isotope
dilution mass spectrometry.
Exposure to medicines that predispose to renal impairment
or hypotension [non-steroidal anti-inflammatory drugs
(NSAIDs), angiotensin-converting enzyme inhibitors (ACEi), an-
giotensin II receptor antagonists (ARB), diuretics, b-blockers] in
3 months prior to the reference AKI was ascertained from dis-
pensed community prescribing data.
The laboratory database was used to calculate baseline renal
function and episodes of AKI as described above. The median
creatinine was calculated if there was more than one serum cre-
atinine measurement taken on the same day.
Statistical analysis
Baseline characteristics were summarized using means and
standard deviations (SDs) for normally distributed continuous
data or medians and interquartile ranges for skewed data.
Categorical variables were summarized using frequencies and
percentages. Comparison of baseline data for recurrent AKI ver-
sus first AKI were made using t-tests, Chi-squared tests and
Mann–Whitney tests, as appropriate. Kaplan–Meier survival
curves were used to estimate and compare survival function of
patient with recurrent AKI versus first-time AKI at index and to
calculate median survival time in the two groups. Cox propor-
tional hazard models were used to examine the association be-
tween AKI status (whether recurrent AKI or first AKI) and
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mortality. The effect size of the association was provided by the
hazard ratio (HR) of recurrent AKI versus first AKI unadjusted or
adjusted for patients’ demographics characteristics, comorbid-
ity and prior medication. Covariates included in the model were
based on clinical expertise and previous evidence in this area.
Several covariates included in the model violated the propor-
tional hazards assumptions. However, when the model was run
without these covariates, the effect of recurrent AKI remained
similar. The covariates that violate the assumptions only con-
tribute a small proportion of variance in the model and inclu-
sion of all variables improved the fit of the model, tested using
the Harrell’s C statistic. Additionally, the Kaplan–Meier survival
curves suggest that the hazards do not appear to vary over time.
Covariates included in the final model were age, sex, diabe-
tes mellitus, AKI stage of reference AKI, derivation (using the
SIMD deciles), previous myocardial infarction (MI), peripheral
vascular disease, cerebrovascular disease and use of diuretics,
ACEi or ARB, NSAIDs and b-blockers in the 3 months prior to the
reference AKI.
Covariates were tested for collinearity, and no collinear vari-
ables were included in the final model.
All analyses were carried out in IBM SPSS (version 21) and
STATA (version 14) software. A P < 0.05 was considered statisti-
cally significant.
Missing data
From the recurrent AKI group 7 patients and from the non-
recurrent AKI group 51 patients had missing SIMD decile. These
patients were included with missing SIMD data.
RESULTS
Participants
Figure 1 represents a flowchart of the patient cohort selection
and exclusions. The study assessed 255 466 patients who had
creatinine measurements taken between 2003 and 2009. A total
of 721 patients were excluded as they were receiving RRT. A to-
tal of 116 630 patients were excluded as they had creatinine
measurements only in 2009 and none in 2003–08. A total of 1667
patients with 13 634 creatinine measurements were excluded as
they were <18 years old at the time of creatinine measure-
ments. Among the 136 448 eligible patients, 1 167 329 creatinine
measurements were taken over the time period 2003–09. A total
of 7128 (5.2%) patients experienced an episode of AKI at any
time in the study period.
In 2009, there were 3533 patients identified as having experi-
enced an AKI, of which 880 (25%) had at least one prior AKI in
the period 2003–08. The cumulative total in the 6-year time pe-
riod prior to 2009 was 1740 AKI events. In total, 15 cases were
reviewed where the time between the previous AKI and refer-
ence AKI was 14 days. This led to nine patients being excluded
as eight were found to be unresolved AKI events and one case
was progressive CKD. A total of 3524 patients with 5202 AKI
events were included in the final analysis. The majority of these
patients had a single episode of AKI, in 2009, with no evidence
of previous AKI 2003–08, 2644 (75%). A total of 880 patients (25%)
had prior AKI between 2003 and 2009.
Baseline characteristics
Table 1 describes patient characteristics and demographics for
those with and without recurrent AKI.
In the majority of patients with recurrent AKI, 517 (58.8%)
had one previous AKI episode detected between 2003 and 2008,
195 (22.2%) had two previous AKI episodes, 76 (8.6%) had three
previous AKI episodes and 92 (10.4%) had more than four previ-
ous AKI episodes. The median time between the reference AKI
and previous AKI episode in 2003–08 was 1.21 years (interquar-
tile range (IQR) ¼ 0.58–2.43 years).
Survival
A total of 2501/3524 (71.0%) patients died over a median (IQR)
follow-up of 3.17 years (0.28–9.19 years). In the non-recurrent
AKI group, 1776/2644 (67.2%) patients died over a median (IQR)
follow-up of 3.86 years (0.33–9.28 years). For patients with recur-
rent AKI, 725/880 (82.4%) patients died over a median (IQR) fol-
low-up time of 1.57 years (0.18–6.48 years). Figure 2 shows the
Kaplan–Meier survival curves for the two groups. Overall sur-
vival was significantly shorter in the group identified to have re-
current AKI (HR ¼ 1.49, 95% CI 1.37–1.63; P< 0.001). There was no
difference in survival among people with recurrent AKI when
comparing the different stages of prior AKI (Figure 3). There was
also no difference in survival when comparing those that had
experienced a more recent recurrent AKI (previous AKI within
365 days of index AKI) compared with those who had experi-
enced a previous AKI less recently (previous AKI 365 days prior
to index AKI) (Figure 4). The adjusted survival model presented
in Table 2 showed that risk of mortality following recurrent AKI
was significantly increased compared with first AKI (HR ¼ 1.25,
95% CI 1.14–1.37; P< 0.001). In addition, increasing AKI stage at
the reference AKI, male sex, increasing age, diuretic use, depri-
vation, baseline eGFR, and previous MI and cerebrovascular dis-
ease were all associated with increased risk of mortality
(Table 2). Use of ACEi or ARB, NSAIDs and b-blockers in
3 months prior to AKI were all associated with decreased risk of
mortality (HR ¼ 0.72, 95% CI 0.66–0.78; P< 0.001, HR ¼ 0.81, 95%
CI 0.70–0.93; P¼ 0.002 and HR ¼ 0.89, 95% CI 0.81–0.98; P¼ 0.016,
respectively).
DISCUSSION
We found that patients with recurrent AKI had increased risk of
death compared with those with a single episode of AKI.
Recurrent AKI was an independent predictor of mortality after
adjustment for confounders including age, sex, deprivation, co-
morbidities, underlying renal impairment and medicines that
predispose to renal impairment or hypotension. Increasing
stage of reference AKI, increasing age, deprivation, lower base-
line eGFR, previous MI and cerebrovascular disease, male sex
and diuretic use were all associated with an increased risk of
mortality in patients with recurrent AKI.
Our findings showed that patients with a baseline eGFR 45–
59 mL/min/1.73 m2 and 30–44 mL/min/1.73 m2 had increased
risk of mortality compared with those with a baseline eGFR
>60 mL/min/1.73 m2; however, this relationship was not true in
the groups with baseline eGFR 15–29 mL/min/1.73 m2 and
<15 mL/min/1.73 m2. The results may be due to the smaller
numbers in these groups, the fact that these groups are more
likely to already be under nephrology care or that the underly-
ing pathological processes that are driving increased mortality
in recurrent AKI are already present as part of advancing CKD.
Studies in animal models have demonstrated that AKI
results in permanent damage to the microvascular structure of
the kidney and maladaptive repair mechanisms that result in
inflammatory and fibrotic changes. This can lead to progressive
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structural and functional kidney damage and may potentiate
the effects of recurrent injury [21, 22]. In a study of patients with
diabetes mellitus and recurrent episodes of AKI, each episode of
AKI was shown to have a cumulative increase in risk of future
development of CKD, with each AKI episode doubling the risk of
CKD [6]. This finding of increasing risk of CKD with recurrent
AKI episodes has been replicated in cohorts including patients
without diabetes mellitus [5, 7, 8]. In addition, recurrent AKI has
also been shown to be associated with increased mortality com-
pared with those with a single AKI episode [4, 5, 7, 9].
Studies have attempted to define risk factors for developing
recurrent AKI. Harris et al. [7] did not find demographics (age,
male sex, black ethnicity), baseline renal function, duration of
AKI or comorbidities (CKD, hypertension, diabetes mellitus) to
255,466
paents with 2,119,641 
creanine measurements 2003-
2009
136,448 paents with 1,667,329 
creanine measurements 
7,128 paents with 11,565 
unique AKI cases
4,326 paents with 7,518 
unique AKI cases when 1st AKI 
2009 merged with all 2003-2008 
AKI
3,533 paents with 5273 unique 
AKI cases when 1st AKI 2009 + 
previous AKIs 2003-2008 
(paents removed if AKI 2003-
2008 but none in 2009)
15 cases reviewed where AKI≤14 
days from 1st 2009 AKI, 9 
paents, 69 AKI events excluded
Recurrent AKI 2003-2008
880 paents with 2560 unique 
AKI cases
No recurrent AKI 2003-2008
2644 paents/unique AKI cases
721 paents excluded from 
renal registry data
116,630 paents/1,950,678 
measurement as no Cr 
measurements 2003-2008
1,667 paents/13634 Cr 
measurements excluded as <18 
yrs old
FIGURE 1: Summary of patient cohorts and exclusions.
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be associated with recurrent AKI. They showed only the pres-
ence of AKI at time of hospital admission to be associated with
recurrent AKI. One proposed explanation for this is that patients
with highest risk of developing recurrent AKI, such as those
with multi-morbidity or severe illness, are more likely not to re-
cover and therefore would not be exposed to the future risk of
recurrence. However, more recent studies have shown different
results. Rodriguez et al. [5] showed that Type 2 diabetes mellitus,
ischaemic heart disease and higher serum creatinine at the
time of first AKI were all independently associated with an in-
creased risk of further episodes of AKI, and Siew et al. [9] showed
that older age, lower baseline eGFR, lower serum albumin, con-
gestive heart failure, advanced liver disease, dementia, diabetes
mellitus and coronary artery disease were all associated with
recurrent AKI. Most recently a large retrospective cohort study
showed that 28.6% of their population who had previous AKI ex-
perienced recurrent AKI. They found that patients who experi-
enced recurrent AKI were older and had more co-morbidities
compared with those who had survived a single AKI, but did not
go on to have recurrent AKI [4]. Our study supports these
findings with 25% of patients experiencing recurrent AKI, and
that this group was older with more co-morbidities.
Rodriguez et al. [5] showed that among the patients they ex-
amined with recurrent AKI episodes, 44% of them developed
their second AKI episode during the first 6-month time period
following initial discharge, with this number increasing further
to 58% at 1 year. They demonstrated that cardiovascular events
were more common in patients with recurrent AKI and found
that when they followed patients up over 4 years following their
first AKI, the most common cause of death was a cardiovascular
event followed by malignancies and infections. They also dem-
onstrated that mortality was higher in the group of patients
who had a recurrent AKI in comparison with those with a single
episode. Similarly, Siew et al. [9] showed that of the 25% of pa-
tient who developed recurrent AKI, 58% had occurred within the
90 days following discharge from the initial AKI and that
patients who had developed recurrent AKI had a higher risk of
death at 1 year compared with those who did not have recurrent
AKI (35% versus 18%; P< 0.001). We have replicated this finding
showing that patients who have evidence of recurrent AKI in
Table 1. Baseline characteristics: recurrent AKI versus no evidence of recurrent AKI
Characteristic Recurrent AKI 2003–08 No recurrent AKI 2003–08 P-value
Patients, n 880 2644
Unique AKI cases, n 2558 2644
Age, mean (SD), years 72.54 (15.6) 68.69 (18) <0.001
Baseline SCr, median (IQR), mmol/L 91 (65–124) 74 (58–94) <0.001
Sex, n (%)
Female 479 (54.4) 1524 (57.6) 0.096
Male 401 (45.6) 1120 (42.4)
AKI stage, n (%)
1 634 (72) 1961 (74.2) 0.029
2 129 (14.7) 416 (15.7)
3 117 (13.3) 269 (10.2)
Source of requesting Cr from start of AKI, n (%)
Hospital consultant 2067 (80.8) 2085 (78.9) 0.136
General practitioner 488 (19.1) 546 (20.7)
Missing 3 (0.1) 13 (0.5)
SIMD, n (%) Some missing
1–3 (most deprived) 231 (26.3) 649 (24.5) 0.691
4–7 355 (40.3) 1083 (41)
8–10 (least deprived) 287 (32.6) 861 (32.6)
Charlson Comorbidity Index, n (%)
Low (0) 124 (14.1) 926 (35) <0.001
Medium (1 or 2) 341 (38.8) 1095 (41.4)
High (3) 415 (47.2) 623 (23.6)
Baseline eGFR (from median creatinine previous 365 days), n (%), mL/min/1.73 m2
60 487 (55.3) 2069 (78.2) <0.001
45–59 182 (20.7) 323 (12.2)
30–44 139 (15.8) 196 (7.4)
15–29 63 (7.2) 49 (1.9)
<15 9 (1) 8 (0.3)
Diabetes mellitus
Type 1 26 (3) 43 (1.6) <0.001
Type 2 277 (31.5) 557 (21)
Diuretic 451 (51.2) 1085 (41) <0.001
ACEi/ARB 346 (39.3) 1042 (39.4) 0.961
NSAID 69 (7.8) 308 (11.6) 0.002
b-blocker 290 (33) 664 (25.1) <0.001
MI 157 (17.8) 328 (12.4) <0.001
Peripheral vascular disease 15 (1.7) 13 (0.5) <0.001
Cerebrovascular disease 204 (23.2) 361 (13.7) <0.001
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the previous 6-year period have higher future mortality than
patients who have no previous evidence of AKI.
Preventing recurrent AKI may currently be an under-utilized
mechanism of reducing the longer term implications such as car-
diovascular disease and CKD. A previous study has shown that
only a minority of patients that survive AKI are referred for ne-
phrology follow-up [12]. The optimal care and follow-up after AKI
remain to be established. Due to the relationship between AKI
and cardiovascular disease, CKD and mortality, there is a need to
define a high-risk population. This may then influence how
patients with AKI are followed-up and has the possibility of re-
ducing future morbidity and mortality. Our study aimed to iden-
tify risk factors that were associated with increased mortality
following recurrent AKI. Our data show that patients who have
experienced a recurrent AKI are less likely to be prescribed
NSAIDs in the 3 months prior to the reference AKI. This may sug-
gest that preventative measures such as avoiding prescribing
nephrotoxic medications, including NSAIDs, to patients who pre-
viously have had an AKI to prevent future risk of AKI is being
considered and employed. Therefore, this may represent a selec-
tion bias in our study. When adjusting for drugs used in the
3 months prior to AKI, ACEi/ARB, NSAIDs and b-blockers were all
associated with a lower risk of mortality. Again, this
may represent selection bias but it may also be that patients who
are on these medications may get AKI for different reasons that
might be associated with a lower risk of future mortality. For ex-
ample, patients taking ACEi/ARB will be more susceptible to AKI
if they become dehydrated and continue taking their medica-
tions, whereas individuals not on ACEi/ARB may require a more
severe illness or ‘hit’ for them to develop AKI.
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FIGURE 2: Kaplan–Meier plot of overall survival in patients with recurrent AKI compared with patients with no evidence of recurrent AKI.
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FIGURE 3: Kaplan–Meier plot of overall survival in patients with recurrent AKI Stage 2 or 3 compared with patients with recurrent AKI Stage 1 and patients with no
evidence of recurrent AKI.
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Overall, our results suggest that recurrent AKI is a marker of
multi-morbidity and advancing age but when adjusting for
these confounders, recurrent AKI also appears to be an indepen-
dent risk factor for future mortality. The limitations of observa-
tional data and confounding have made it difficult to
understand why AKI and recurrent AKI are associated with in-
creased mortality. The prevention of recurrent AKI may have an
impact on reducing future mortality but focusing on individual
patient risk factors and comorbidities may also change how we
manage such patients and plan future care.
Strengths of our study include a large sample size, assessing
136 448 eligible patients with 1 167 329 creatinine measurements
and 3524 patients with AKI with a median follow-up of
3.17 years. We have used the standardized KDIGO definition of
AKI and the widely used NHS England AKI algorithm to define
AKI.
Our data also include patients that have had an AKI in the
community as well as hospital-related AKI, which to our knowl-
edge other studies have not [4, 5, 7, 9, 23]. This broad patient
population allows for greater generalizability of the results. This
study also has a number of limitations. The study is based on
observational data and is therefore limited by confounding. AKI
was defined using the creatinine-based component of the
KDIGO definition. Urine output data are poorly recorded in the
hospital setting and are not part of routinely collected data;
therefore, we were unable to utilize this in defining cases of
AKI, which may have been a more sensitive marker, and as a re-
sult we may have underestimated AKI. There are a number of
other unmeasured confounders, including proteinuria prior to
or follow AKI, hypertension, weight/BMI, smoking status, medi-
cations prescribed in hospital and cause of AKI that also limit
the study.
A further limitation is that although we identified patients
who had an AKI in 2009 and no previous evidence of AKI in the
years 2003–08 prior to this, it is not possible to say that these
patients did not have a further AKI event in the future prior to
death or end of follow-up.
This observational study suggests that increasing stage of
reference AKI, increasing age, deprivation, lower baseline eGFR,
previous MI and cerebrovascular disease, male sex and diuretic
use were all associated with an increased risk of mortality in
patients with recurrent AKI. After adjusting for patient charac-
teristics and comorbidities the increase in mortality is indepen-
dently associated with recurrent AKI and is not solely explained
by other risk factors. This has implications for how we manage
Time_Between_AKI 
No recurrent AKI
Recurrent AKI < 365 days
previously
Recurrent AKI < 365 days
previously – censored
Recurrent AK ≥ 365 days
previously
Recurrent AK ≥ 365 days
previously – censored
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FIGURE 4: Kaplan–Meier plot of overall survival in patients with recurrent AKI with previous AKI <365 days previously compared with patients with recurrent AKI 365
days previously and patients with no evidence of recurrent AKI.
Table 2. Cox regression model for mortality
Variable HR (95% CI) P-value
Recurrent AKI 1.249 (1.141–1.368) <0.001
No diabetes mellitus 1.00 (reference)
Type 1 diabetes mellitus 0.975 (0.666–1/426) 0.895
Type 2 diabetes mellitus 0.981 (0.892–1.078) 0.686
AKI
Stage 1 1.00 (reference)
Stage 2 1.524 (1.369–1.696 <0.001
Stage 3 1.900 (1.673–2.158 <0.001
Sex (F ¼ 0, M ¼ 1) 1.220 (1.124–1.324) <0.001
Age at last AKI event, years 1.045 (1.042–1.049) <0.001
Diuretic 1.084 (0.993–1.182) 0.07
ACEi/ARB 0.716 (0.657–0.781) <0.001
NSAIDS 0.808 (0.704–0.928) 0.002
b-blocker 0.893 (0.814–0.979) 0.016
Deprivation (least 1–3) 1.00 (reference)
Deprivation (middle 4–7) 1.052 (0.96–1.153) 0.227
Deprivation (most 8–10) 1.159 (1.042–1.29) 0.007
MI 1.161 (10.38–1.298) 0.009
Peripheral vascular disease 1.305 (0.863–1.974) 0.207
Cerebrovascular disease 1.170 (1.057–1.296) 0.002
Baseline eGFR 60 1.00 (reference)
Baseline eGFR 45–59 1.121 (1.002–1.255) 0.046
Baseline eGFR 30–44 1.236 (1.084–1.409) 0.002
Baseline eGFR 15–29 1.112 (0.901–1.372) 0.323
Baseline eGFR <15 0.984 (0.573–1.689) 0.953
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and approach patients who experience multiple episodes of
AKI. It is important that we focus on preventing AKI episodes as
well as focusing on managing comorbidities that are likely to
drive episodes of AKI and mortality.
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